Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — For adults with type 2 diabetes and chronic kidney disease, a novel nonsteroidal ...

Please provide your email address to receive an email when new articles are posted on . Mineralocorticoid receptor antagonists disrupt the renin-angiotensin-aldosterone system and provide beneficial ...

Steroidal MRAs particularly benefit patients on dialysis, whereas nonsteroidal MRAs help treat patients with nondialysis-dependent CKD. Steroidal mineralocorticoid receptor antagonists (MRAs) reduce ...

To date, ankylosing spondylitis (AS) has been treated with nonsteroidal anti-inflammatory drugs (NSAIDs), whilst maintaining a conservative dose regimen because of known gastrointestinal side effects.

Credit: Italfarmaco. The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 EPIDYS study. Duvyzat is the first nonsteroidal treatment approved for patients with ...

Panelists discuss how mineralocorticoid receptor antagonists (MRAs) remain underutilized despite being foundational therapy for heart failure with reduced ejection fraction due to clinician fears of ...

Credit: Getty Images Evidence in favor of SGLT2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists for treating patients with diabetic kidney disease is growing. In combination with ...

Table 1. Suggested strategies for analgesic/anti-inflammatory treatment and cardiovascular prevention among patients with inflammatory disease and different levels of risk of vascular events. Risk of ...